Clinical Trial Update: Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Dociparstat in adults with severe COVID-19 at high risk of respiratory failure shows termination across Phase 2/3 with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019
• Lung Injury
• Respiratory Syndrome Coronavirus 2 Infection

Drugs mentioned

• Dociparstat (dociparstat)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Coronavirus Disease 2019 (COVID-19), Acute Lung Injury | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-08-30